Dr. Amynah Pradhan: The Delta Opioid Receptor and the Migraine Paradox

Chronic migraine sits at a peculiar crossroads in opioid pharmacology: sustained mu opioid receptor activation is a well-documented driver of medication-overuse headache, while preclinical evidence points to delta opioid receptor agonism as a candidate to relieve the same disorder. Dr. Amynah Pradhan's lab at the University of Illinois at Chicago has spent years pulling apart that asymmetry — combining mouse models of chronic migraine, cortical spreading depression, and opioid-induced hyperalgesia with peptidomic screens and conditional genetics to ask where the two receptors diverge anatomically, pharmacologically, and in the chronic disease state. The work sits inside a larger argument Dr. Pradhan returns to often: that organisms in chronic pain are fundamentally different biological systems than naïve ones, and that drug discovery fails when it pretends otherwise. For her, this line of work is also personal — the delta opioid receptor has been her scientific focus for nearly two decades, through failed clinical trials in depression and pain, and migraine may finally be where it finds a clinical home.

About the Guest

Dr. Amynah Pradhan is Associate Professor of Psychiatry at the University of Illinois at Chicago, where her lab studies opioid receptor biology in the context of headache disorders, chronic pain, and their comorbid emotional states. She trained in pharmacology at McGill University with Paul Clarke and completed postdoctoral work at AstraZeneca, with Brigitte Kieffer in Strasbourg, and with Chris Evans at UCLA. Her research integrates behavioral pharmacology, ligand-directed signaling, and mouse models of migraine, and has become central to the small community of basic pharmacologists working inside the headache field.

Scientific Themes of the Conversation

• The mu/delta asymmetry in migraine — why two receptors in the same family produce opposite clinical outcomes

• Chronic disease states as fundamentally altered biological systems — and what that means for drug discovery

• Ligand-directed signaling and receptor trafficking — how internalization shapes tolerance and adverse effects

• The emotional circuitry of chronic pain — and the kappa opioid / dynorphin link

• The unfinished GPCR frontier — PACAP, CGRP, and the persistent antibody problem

• Career mobility through collaboration — how a headache neurologist redirected two decades of work

Key Insights from the Conversation

The yin-yang that organizes the lab. Mu opioid agonists, in chronic use, exacerbate migraine and drive medication-overuse headache. Delta opioid agonists appear to relieve the same symptoms — pain, negative affect, and aura-related signs in preclinical models. Dr. Pradhan treats the contrast not as a side story but as the organizing question of her work.

Chronic states are not scaled-up acute states. One of Dr. Pradhan's recurring arguments is that the organism in a chronic disease state is fundamentally altered, and that drug candidates fail in clinical trials partly because they are validated in naïve animals that do not resemble the patients they will eventually treat.

Internalization is a design choice, not a side effect. Earlier work in her career showed that high-internalizing delta agonists drive receptor downregulation and tolerance, while low-internalizing agonists uncouple the receptor from ion channels without losing it. The ideal delta agonist, by her account, would be non-internalizing, brain-penetrant, long-half-life, and directed at forebrain circuits where emotional salience of pain lives.

Delta agonists may finally have a disease. After failed trials in depression and pain, Dr. Pradhan argues that migraine — with its emotional comorbidity, its anatomical overlap with delta receptor expression, and its distinctive pain mechanisms — may be the clinical home the compound class has been looking for. The conviction is quiet but deeply held.

The antibody problem is keeping a field from basic answers. Her "bugaboo": we still do not know reliably where many GPCRs live — which cell type, which compartment, surface versus intracellular — because antibodies for the family are widely unreliable. For a pharmacologist, the resolution problem sits upstream of every other question.

A single collaboration can redirect a career. Her move from pure opioid pharmacology into migraine came from sharing a building with neurologist Andrew Charles at UCLA. She treats this as a generalizable lesson for junior scientists: openness to collaboration is not decorative — it is how fields get rewired.

The invisible labor of being the only one in the room. Toward the end of the conversation, Dr. Pradhan turns to the structural weight carried by women and scientists of color in academia — the cumulative load of committee service, mentorship, and representation — and argues that real support requires institutions to account for it, not just request it.

Episode Timeline

Timestamps were generated using AI for readability.

00:00 Introduction

01:13 From McGill to migraine — a path through four labs

04:19 Why mu worsens migraine and delta relieves it

09:27 What chronic dosing does to the receptor — tolerance, internalization, downregulation

14:17 Designing the delta agonist she wants

17:30 The emotional circuitry of chronic pain — and the kappa link

22:22 CGRP, PACAP, and why GPCR drug discovery is not out of runway

28:54 Biased ligands after the hype cooled

34:08 How you measure migraine in a mouse

40:44 Three aha moments — and why delta agonists may finally have a home

43:28 The hidden cost of being the only one in the room

57:05 What the pandemic did to a mouse colony

Selected Quotes

About this episode

In this episode of the Dr. GPCR podcast, we meet with Dr. Amynah Pradhan. She is an Associate Professor of Psychiatry at the University of Illinois at Chicago. Amynah did her undergrad research measuring IP3 in airway smooth muscle cells and completed a Ph.D. at McGill University in Canada with Dr. Paul Clarck, where she studied opioid receptors. Her next career step took her to AstraZeneca as a postdoctoral trainee, where she studied animal models of pain and sensory neuron sensitive-receptor.

She then returned to academia and worked on opioids as a postdoctoral trainee with Dr. Brigitte Kieffer, where she studied ligand-directed signaling at the delta-opioid receptor. Her career path-defining moment came from a third postdoctoral experience with Dr. Chris Evans at UCLA. Amynah studied how arrestins regulate ligand-directed signaling at delta-opioid receptors, and it is their collaboration with a headache physician-scientist Dr. Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic target to treat headache.

Dr. Amynah Pradhan on the web

• Lab page

• LinkedIn

• Twitter

• Google Scholar

• PubMed

• Dr. GPCR Ecosystem